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Cryptococcosis is a signiﬁcant invasive fungal infection with noteworthy morbidity and mortality, pri-
marily caused by Cryptococcus neoformans and Cryptococcus gattii. In China, C. neoformans var. grubii
(especially molecular type VNI) is the most common variety in the environment and responsible for
the majority of cryptococcal infections. C. gattii infections are quite rare in China and the primary molec-
ular type is VGI, which is closely related to C. gattii isolates in Australia. Interestingly, the majority of
cryptococcosis in China were reported in the HIV-uninfected patients (especially immunocompetent
hosts). This unique phenomenon may be attributed to multiple polymorphisms in the genes encoding
mannose-binding lectin (MBL) and Fc-gamma receptor 2B (FCGR2B) in the Han population, the major eth-
nic group in China. Compared to immunocompromised patients, immunocompetent patients with cryp-
tococcal meningitis often presented with more intense inﬂammatory responses and more severe
neurological complications, but less fungal burdens and disseminated infection. The overall prognosis,
which is independently associated with amphotericin B-based initial therapy, is similar between
immunocompetent and immunocompromised patients. In addition, intrathecal administration of
amphotericin B has been proved to be an effective adjunctive treatment for cryptococcosis in China.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cryptococcus is an important fungal pathogen causing life-
threatening meningitis of signiﬁcant morbidity and mortality.
Among the 70 identiﬁed species of Cryptococcus, Cryptococcus neo-
formans and Cryptococcus gattii are the major causative agents of
human cryptococcosis (Kurtzman et al., 2010). While C. neoformans
is a major fungal pathogen causing infections in immunocompro-
mised individuals such as AIDS patients, C. gattii has long been con-
sidered as the culprit causing cryptococcosis in immunocompetent
hosts, recently highlighted in the outbreaks in Canada (British
Columbia) and the United States Paciﬁc Northwest (Datta et al.,
2009; Galanis et al., 2010; Heitman et al., 2010; Sorrell, 2001).
These two species are genetically related to each other, however,
they vary in ecological niches, geographic distribution, and patho-
genic characteristics. C. neoformans has a global distribution and is
closely associated with avian habitats, while most C. gattii strains
have been isolated from North America and Australia, and are com-
monly identiﬁed in Eucalyptus trees in the environment (Ellis andPfeiffer, 1990). In addition, C. gattii infections often cause more fre-
quent neurological complications than C. neoformans. It seems C.
gattii is less sensitive to antifungal therapy than C. neoformans,
therefore, more aggressive interventions are usually required in
the treatment of C. gattii infections (Newton et al., 2002; Perfect
et al., 2010; Speed and Dunt, 1995).
China is the third largest and the most populous (over 1.3 bil-
lion people) country in the world. The majority of people in
China reside in the temperate and subtropical regions, a climate
amenable for fungal growth and spread. In fact, the increasing
number of immunocompromised population including patients
with HIV infection, malignant tumors, organ or stem-cell trans-
plantation, and autoimmune diseases during the past several dec-
ades in China has led to a rapid elevation of the incidence of
invasive fungal infections such as cryptococcosis, which become
a serious threat to the public health (Trey et al., 2011; Wang and
Wang, 2010; Wu et al., 2011a; Wu and Lu, 2008; Yang et al.,
2010). Unfortunately, relatively little is known about the diversity
and epidemiology of the pathogenic Cryptococcus species complex
in China. In this article, the ecology, epidemiology, and population
genetics of C. neoformans and C. gattii in China will be reviewed and
compared with data from other countries. In addition, the unique
clinical features and epidemiology of cryptococcosis in China, and
the Chinese physicians’ management experience on cryptococcosis
will also be discussed in the present review.
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C. neoformans and C. gattii in China
Human cryptococcal infections are thought to be acquired by
inhalation of airborne spores or desiccated yeast cells from the
environment (Lin and Heitman, 2006). Therefore, investigation of
the geographic distribution and environmental niches of C. neofor-
mans and C. gattii allows us to better understand the potential
impacts of these environmental pathogenic fungi on human health.
In China, ecological studies of C. neoformans and C. gattii were
initiated relatively late, andmost studies were focused on the iden-
tiﬁcation of cryptococcal strains from avian excreta. In 1993, Li et al.
isolated 51 C. neoformans isolates from 36 samples of pigeon drop-
pings in Nanjing city, East China (Li et al., 1993). Among them, 40
(78%) and 11 (22%) isolates were identiﬁed as serotype A and sero-
type AD, respectively, based on slide agglutination assays.
Interestingly, both C. neoformans serotype A and serotype AD iso-
lates were concurrently isolated from some samples. In 2000, Li
et al. isolated 32 C. neoformans serotype A isolates from 144 sam-
ples of pigeon droppings in private and public pigeon shelters in
Shanghai, China (Li et al., 2000). In 2011, ﬁve C. neoformans serotype
A strains were identiﬁed from 143 samples of fresh domestic
pigeons droppings in Beijing (Wu and Li, 2011). In 2012, a total of
358 C. neoformans isolates were isolated from 620 samples of avian
excreta in 10 major cities from 20 to 50 North latitude (Li et al.,
2012). Mycological tests of 101 isolates showed that all of them
were C. neoformans serotype A and mating type a, which was con-
sistent with the geographic distribution of cryptococcosis in China.
The isolation rate of C. neoformans in the G2 region (30–40N) was
the highest (50%), followed by the G3 region (20–30N) (29%) and
the G1 region (40–50N) (13%). Unfortunately, the molecular types
of these environmental isolates were not determined. Recently, Lin
et al. isolated 80 cryptococcal strains from 1372 avian fecal samples
collected from 15 provinces in mainland China (Lin et al., 2013). All
the 80 strains were identiﬁed as C. neoformansmolecular type VNIc
based on PCR ﬁngerprinting, which is consistent with the major
molecular type of clinical isolates in China (Chen et al., 2008).Fig. 1. Summary of ecological studies on C. neoformans conducted in mainland China be
avian fecal samples from 16 provinces in China (Li et al., 1993, 2012; Li et al., 2000; Lin e
regions, which was relatively higher in Southeast regions. The shadowed areas represenTaken together, avian habitats were an important natural reser-
voir for C. neoformans in China, and C. neoformans serotype A
strains (96%) were the predominant species in this environment.
In total, 283 cryptococcal isolates were isolated from pigeon drop-
pings in 16 provinces in mainland China (Fig. 1). The average isola-
tion rate was 12.9%, which is signiﬁcantly lower than that in other
countries (Castanon-Olivares and Lopez-Martinez, 1994; Romeo
et al., 2012). The signiﬁcant difference of isolation rates of crypto-
coccal isolates between China and other countries may be attribu-
ted to differences in the isolation methods, sample quality, and
some environmental factors. In addition, the geographic distribu-
tion of C. neoformans is associated with the longitude and climate.
The southeastern region (tropical and subtropical regions with
warm and wet climate) appears to be more appropriate for fungal
growth and propagation compared with other regions in China.
However, the ecological data from West China are currently not
available, which highlights ecological and epidemiological studies
in this area in the future.
Unlike C. neoformans that is mainly associated with pigeon
droppings, C. gattii strains are mostly isolated from trees and
decayed wood. For example, C. gattii strains, especially strains of
the molecular type VGI, were closely associated with Eucalyptus
trees in Australia and elsewhere (Chakrabarti et al., 1997; Ellis
and Pfeiffer, 1990; Montenegro and Paula, 2000; Sorrell, 2001).
Eucalyptus camaldulensis trees were imported from Australia to
China and widely distributed between 17N and 33N, including
Jiangxi, Guangdong, Guangxi, and Zhejiang provinces. Currently,
there is only one report on C. gattii ecology in China. Li et al. col-
lected 819 samples of ﬂower, bud, leaf, decayed wood, and bark
from 40 E. camaldulensis trees in the Jiangxi province, China (Li
et al., 2012). However, no C. gattii strains were isolated from these
tree samples, which may be due to the physiological adaptation of
E. camaldulensis to the changes of climate or ecological environ-
ment. Molecular identiﬁcation methods, which are more sensitive
than culture-dependent approaches, may be useful in ecological
studies of C. gattii in China. In addition, identiﬁcation and charac-
terization of other ecological niches of C. gattii should also between 1993 and 2013. A total of 283 cryptococcal strains were isolated from 2194
t al., 2013; Wu et al., 2011b). The positive rate of isolation was variable in different
ted those provinces where no ecological data about C. neoformans were available.
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indica, Pithecolobium dulce, Syzygium cumini, and Manilkara hexan-
dra have been demonstrated to be more appropriate environmen-
tal reservoirs for C. gattii than Eucalyptus in India, (Grover et al.,
2007; Randhawa et al., 2006, 2008).3. Characteristics of clinical isolates of C. neoformans and
C. gattii in China
C. neoformans var. grubii (serotype A) is the most common cau-
sative agent of cryptococcal meningitis worldwide (80%), espe-
cially in AIDS patients. C. gattii infections, which have been
mainly reported in Australia and America, are much less prevalent
than infections caused by C. neoformans (Chayakulkeeree and
Perfect, 2006). In Asia, most population genetic studies of the C.
neoformans species complex were from Thailand and India. Since
the 1990s, several studies have been performed to explore the epi-
demiology of clinical isolates of C. neoformans and C. gattii in China
based on serological and/or molecular tests.
Most clinical isolates of the pathogenic C. neoformans species
complex in China were identiﬁed as serotype A and B strains, while
serotype D and AD strains account for a small percentage, which is
consistent with the results of ecological studies. In 1987, Li et al.
conducted the ﬁrst serotyping study of clinical cryptococcal iso-
lates from 9 regions in mainland China, and identiﬁed 49 C. neofor-
mans serotype A and 9 C. gattii serotype B strains (Li et al., 1987).
The authors concluded that serotype A and B strains were the
major causative agents of cryptococcosis in China, and even in
Asia, which was supported by many subsequent studies. For exam-
ple, Li et al. identiﬁed 17 serotype A (89.5%) and 2 serotype B
(10.5%) strains among 19 cryptococcal clinical strains isolated from
Shanghai and Nanjing cities in 1993 (Li et al., 1993). Another study
reported 20 serotype A (95.2%) and 1 serotype B strains (4.8%) iso-
lated from patients in Taiwan, and all these isolates were mating
type alpha (19/19) (Hsu et al., 1994).
Several studies have characterized the molecular types of clini-
cal cryptococcal isolates from China. Based on PCR-ﬁngerprinting
and multilocus sequence typing (MLST), Chen et al. identiﬁed
120 (93%) VNI (C. neoformans serotype A) and 9 (7%) VGI (C. gattii
serotype B) strains among a collection of 129 clinical cryptococcal
isolates from sixteen provinces in mainland China (Chen et al.,
2008). Phylogenetic analyses grouped all VNI strains into a unique
cluster (the VNIc cluster) with environmental strains reported in
an ecological study in China (Lin et al., 2013). C. neoformans usually
causes cryptococcosis in immunocompromised patients (Heitman
et al., 2010). However, most VNI isolates (84, 70%) in this study
were isolated from patients with no signiﬁcant immunodeﬁciency
(Chen et al., 2008). Feng et al. also reported that the predominant
molecular type was VNI among clinical cryptococcal isolates from
China (Feng et al., 2008). The authors identiﬁed 103 VNI isolates
(89.5%) from 115 clinical isolates in mainland China. Except one
strain that was mating type a (serotype D, molecular type VNIV),
other strains were identiﬁed to be mating type alpha. In addition,
most strains (75/78, 96.2%) were isolated from HIV-uninfected
patients. Among the 115 clinical cryptococcal isolates, 9 (7.8%)
strains were identiﬁed to be C. gattii, which were isolated from
East (subtropical zone) and South China (tropical zone). The 9 C.
gattii strains were further classiﬁed into molecular types VGI (8,
7.0%) and VGII (1, 0.9%). Subsequently, Chen et al. compared the
genotypic distribution of cryptococcal isolates between
HIV-positive and HIV-negative patients in southeast China using
PCR ﬁngerprinting and DNA sequencing of the internal transcribed
spacers of rDNA (ITS region) and the capsule-associated gene
(CAP59) (Chen et al., 2010). A total of 109 C. neoformans and 12 C.
gattii strains were isolated from cryptococcosis patients. All the12 C. gattii (11 VGI and 1 VGII molecular types) were isolated from
HIV-uninfected patients. Among the 109 C. neoformans isolates, 89
(82%) and 20 (18%) were isolated from HIV-uninfected and
HIV-infected patients, respectively. In addition, the molecular type
VNI predominated in the C. neoformans clinical isolates (79, 72%)
(Chen et al., 2010). In 2010, Liaw et al. characterized 100 clinical
cryptococcal strains from a teaching hospital in Taiwan (Liaw
et al., 2010). Based on PCR ﬁngerprinting, 99 strains were identiﬁed
as C. neoformans serotype A (98 VNI and 1 VNII molecular types)
and only one was identiﬁed as C. gattii serotype B (molecular type
VGI). Tseng and his colleagues analyzed the molecular types of 219
isolates from 20 hospitals throughout Taiwan during 1997–2010
(Tseng et al., 2013). They identiﬁed 210 (95.9%) C. neoformans
isolates including 206 VNI and 4 VNII isolates, and 9 C. gattii
isolates including 3 VGI and 6 VGII isolates. The VNI molecular type
predominated in both HIV-infected (98.1%, 53/54) and
HIV-uninfected patients (91.9%, 137/149) and C. gattii was more
commonly isolated from HIV-uninfected patients (88.9%, 8/9) than
HIV-infected patients in Taiwan, which is consistent with the
results in mainland China.
Multilocus microsatellite typing (MLMT) has been successfully
used to discriminate a number of pathogenic fungi (De-Valk
et al., 2007; Illnait-Zaragozi et al., 2010). MLMT in which highly
polymorphic microsatellite markers are used as genotyping mark-
ers exhibited signiﬁcant higher discriminatory power than house-
keeping genes-based MLST, therefore, MLMT can discriminate
closely related strains that may be genetically identical based on
MLST. Using MLMT with 9 serotype A-speciﬁc microsatellite mark-
ers, Zhu et al. characterized 43 C. neoformans serotype A strains
from 6 Chinese cities in 2009 (Zhu et al., 2009). Among the 43 ser-
otype A strains, genotype MLMT-17 predominated in both clinical
(86.67%, 26/30) and environmental isolates (70%, 7/10), while
other genotypes including MLMT-14, 16, 29, 39 and 40 were rare.
The predominant genotype MLMT-17 has also been reported in
another two studies on C. neoformans clinical isolates from
Guizhou (85.7%), Guangxi (96.7%), and Jilin (91.4%) provinces in
mainland China (Gao and Wang, 2013; Kang et al., 2013). The
genotype MLMT-17 of C. neoformans is likely the major genotype
in East Asia, which is signiﬁcantly different from the genotypic dis-
tribution of C. neoformans in other countries (Hanafy et al., 2008).
For example, MLMT-22 was the predominant genotype in Africa
and Europe, while genotypes MLMT-13 and MLMT-22 were com-
mon in South America. Based on MLMT analysis, Pan et al. further
explored the genetic diversity of C. neoformans serotype A isolates
in China (Pan et al., 2011, 2012). The 116 C. neoformans serotype A
strains isolated from patients in 15 provinces in Southeast and
Central China were classiﬁed into 62 MLMT genotypes and
grouped into three microsatellite complexes (MCs). Interestingly,
most strains (n = 103) were grouped into MC2. By contrast, MC3,
MC16 and MC8 predominated in C. neoformans serotype A clinical
isolates from India, Japan, and other Southeast Asian countries (i.e.,
Indonesia and Thailand). In addition, most MC2 strains were iso-
lated from HIV-uninfected patients, whereas MC8 strains were
common in HIV-infected patients (Pan et al., 2012).
Taken together, C. neoformans strains of serotype A, molecular
type VNI, and mating type a predominate in both immunocompe-
tent and immunocompromised patients in China (See Table 1).
Interestingly, the majority of those strains were isolated from
HIV-uninfected patients, which is consistent with the results from
other Asian countries such as Vietnam but inconsistent with the
reports from other regions of the world (Chau et al., 2010;
Dromer et al., 1996; Hajjeh et al., 1999; Moosa and Coovadia,
1997). Nevertheless, local geographic differences of genotypic
structure for C. neoformans var. grubii were signiﬁcant in Asia,
which might be due to different founder effects and/or environ-
mental factors (including both ecological and host environment)
Table 1
Clinical Cryptococcus isolates identiﬁed in various regions in China.
Year Region No. of isolates Method Serotype, molecular type, and genotype Reference
1987 9 regions 58 Slide agglutination A (49), B (9) Li et al. (1987)
1993 Shanghai & Nanjing 19 A (17), B (2) Li et al. (1993)
1994 Taiwan 21 Slide agglutination A (20), B(1) Hsu et al. (1994)
2008 16 provinces 129 RFLP, MLST A, VNI (120); B, VGI (9) Chen et al. (2008)
2008 Six regions 115 RFLP, MLST A, VNI (103); AD, VNIII (2); D, VNIV (1); B, VGI (8), VGII (1) Feng et al. (2008))
2009 6 provinces 43a MLMT A; MLMT-14(1), -16(1), 17(36), 29(1), 34(1), 39(1), 40(2) Zhu et al. (2009)
2010 10 provinces 109 RFLP VNI(79), VNII(15), VNIII(2); VGI (11), VGII (1) Chen et al. (2010)
2010 Taiwan 100 RFLP A, VNI(98), VNII(1); B, VGI(1) Liaw et al. (2010))
2013 Taiwan 219 RFLP A, VNI(206), VNII(4); B, VGI (3), VGII(6) Tseng et al. (2013))
2013 Guizhou & Guangxi 58 MLMT MLMT-9, 17, 26, 40, 41 Kang et al. (2013)
2013 Jilin 58 MLMT 9(1), 17(53), 26(1), 40(2), 41(1) Gao and Wang (2013)
2013 15 provinces 116 MLMT MC2(103), MC3(3), MC(12) Pan et al. (2011, 2012)
a Including 10 environmental isolates of C. neoformans.
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formans such as VNIII (serotype AD) and VNIV (serotype D) were
occasionally isolated from Chinese patients and the isolation rate
of these two serotypes in China were lower than that in Europe
and South America (Dromer et al., 1994; Lemmer et al., 2004;
Trilles et al., 2008; Viviani et al., 2006). In addition, C. neoformans
strains in China exhibited relatively low genetic diversity based
on AFLP, MLST, and MLMT analyses, which is consistent with
reports from other Asian countries such as India and Thailand,
and the genetic diversity of Asian strains was generally lower than
strains isolated from other regions of the world
(Barreto-de-Oliveira et al., 2004; Jain et al., 2005; Meyer et al.,
1999; Simwami et al., 2011; Sriburee et al., 2004).
The incidence of C. gattii infection (1–11%), which mainly
occurred in the subtropical and tropical areas (Eastern and
Southern China) such as Guangdong, Zhejiang, Shanghai, and
Taiwan, was signiﬁcant lower than that of C. neoformans infection
(See Table 1). The low incidence of C. gattii infection was close to
that in other Asian countries and Europe, but lower than the aver-
age global incidence of C. gattii infection (20%) (Heitman et al.,
2010). The major C. gattii molecular type in China was VGI,
accounting for 78.9% (30/38) of clinical C. gattii isolates. The isolate
S8012 (ATCC56992 or CBS7229) was initially reported as C. neofor-
mans var. shanghaiensis by Liao et al. in 1980s, but has been molec-
ularly identiﬁed to be VGI recently (Chen et al., 2011; Liao et al.,
1983). Globally, C. gattii VGI isolates predominate in clinical iso-
lates in Australia and Papua New Guinea (Campbell et al., 2005;
Heitman et al., 2010; Sorrell et al., 1996). Based on MLST and phy-
logenetic analyses, it has been conﬁrmed that C. gattii VGI isolates
from China were closely associated with C. gattii strains from
Australia, suggesting that the potential origin and distribution of
C. gattii VGI strains in China (Chen et al., 2011; Feng et al., 2008).
Since 1999, hypervirulent strains of C. gattii VGII molecular type
have caused several outbreaks in Canada (British Columbia) and
the Paciﬁc Northwest United States (Washington and Oregon)
(Datta et al., 2009). The C. gattii VGII strains had been proved to
be the major pathogen causing cryptococcosis in immunocompe-
tent patients in the world (Heitman et al., 2010). In 2007,
Okamoto reported the ﬁrst cryptococcosis case caused by a VGIIa
strain in Japan and Asia (Okamoto et al., 2010). This strain was
identical to the isolate R265 (the Vancouver Island outbreak major
genotype strain) based on MLST, suggesting that this hypervirulent
strain may spread to Asia. In China, a C. gattii VGIIb strain (XH91)
that is closely related to the R272 strain (Vancouver Island out-
break minor genotype strain) was recently isolated from a patient
in Guangdong, China (Feng et al., 2008, 2010). While most C. gattii
infections in China were caused by the VGI molecular type,
isolation of the VGIIb strain from a Chinese patient suggests that
cryptococcosis caused by C. gattii VGII molecular type also exist
in China.4. Epidemiology and molecular genetics of clinical isolates of
C. neoformans and C. gattii in China
Since the ﬁrst cryptococcosis case was described by Buss and
Buschke in 1894, research on cryptococcosis has a 120-year history
(Buschke, 1895; Busse, 1894). Due to the global AIDS pandemic and
wide use of chemotherapy and immunosuppressants, the inci-
dence of cryptococcal infections (especially meningoencephalitis)
has signiﬁcantly increased in the past decades. It has been esti-
mated that the global burden of cryptococcal meningitis was
approximately 957,900 cases per year, resulting in 624,700 deaths
annually (Park et al., 2009). Due to distinct HIV endemic status and
geographic and ethnic factors, the incidence of cryptococcosis var-
ies in different countries and regions (Chen et al., 2000; Friedman
et al., 2005; McCarthy et al., 2006; Mirza et al., 2003). For example,
the annual incidence of cryptococcosis was 6.6 cases per million
person in Australia, 15.6 per 100,000 person in Gauteng Province,
South Africa (Chen et al., 2000; McCarthy et al., 2006). Studies on
the prevalence and epidemiology of cryptococcosis in China have
been very limited. A recent systematic review has reported a total
of 8769 cases of cryptococcosis in mainland China between 1985
and 2010 (Chen et al., 2012). However, the incidence of cryptococ-
cosis in mainland China may be much higher than reported in this
review because of missed and misdiagnosed cases and publication
bias. In 2011, Chen et al. conducted a population-based epidemio-
logical study of cryptococcal meningitis in Taiwan from 2000 to
2007, and reported an annual incidence of 4.7 cases per million
person (Chen and Lai, 2011). In general, the number of reported
cryptococcosis in China has been increasing over recent decades
(Wu et al., 2011a; Chen et al., 2012; Zhu et al., 2010).
Cryptococcosis has been deﬁned as an opportunistic fungal
infection because it mainly occurs in immunocompromised popu-
lations such as patients with AIDS, organ transplantation recipi-
ents, patients with autoimmune diseases. Studies from the U.S.,
France, and Thailand reported a relatively small proportion (17–
35%) of cryptococcosis occurring in patients with apparently
healthy condition (Kiertiburanakul et al., 2006; Pappas et al.,
2001). However, a signiﬁcantly high proportion of cryptococcosis
were reported in immunocompetent individuals in China (See
Table 2) (Chen et al., 2008, 2012; Chen and Lai, 2011; Lu et al.,
1999; Lui et al., 2006; Shih et al., 2000; Tseng et al., 2013; Zhu
et al., 2010). For example, among the 154 cryptococcal meningitis
cases reported at Huashan Hospital, Shanghai, 103 (66.9%) cases
were identiﬁed in immunocompetent individuals (Zhu et al.,
2010). Similarly, 68% of cryptococcal meningitis cases were
reported in immunocompetent individuals in another study per-
formed at Changzheng Hospital, Shanghai (Chen et al., 2008).
Several hospital-based studies conducted in Taiwan reported that
55.3% (Shih et al., 2000), 60.6% (Lu et al., 1999), 25% (Liao et al.,
2012), and 43.5% (Lui et al., 2006) of cryptococcosis cases occurred
Table 2
Demographic features and underlying diseases of cryptococcosis patients with or without HIV infection from hospital-based studies.
Parameter Without HIV infection With HIV infection
Lu et al. (1999) Shih et al. (2000) Zhu et al. (2010) Lui et al. (2006) Liao et al. (2012) Tseng et al. (2013)
Publication year 1999 2000 2010 2006 2012 2013
Region Taiwan Taiwan Shanghai Hong Kong Taiwan Taiwan
Period 1986–1997 1977–1996 1997–2007 1995–2005 1995–2009 1997–2010
No. of Patients 71 94 154 46 72 219
Sex
% (male/total) 64.8% (46/71) 52.8% (59/94) 61.0% (94/154) 60.9% (28/46) 75% (54/72) 67.6% (148/219)
Age (yr)a (15, 83) 37.7 ± 17.5 (4, 83) 38.5 (9, 75) 50.0 ± 3.1 52.5 ± 18.2 (12, 94)
Predisposing factors
HIV/AIDS 19.6% (9/46) 26.4% (19/72) 24.7% (54/219)
Corticosteroids and immunosuppressives 13.6% (21/154) 21.7% (10/46) 18.1% (13/72)
Autoimmune diseases 7.0% (5/71) 10.6% (10/94) 11.0% (17/154) 10.9% (5/46) 6.9% (5/72) 5.0% (11/219)
HBV 21.0% (46/219)
Liver cirrhosis 7.0% (5/71) 6.4% (6/94) 9.7% (15/154) 8.7% (4/46) 16.7% (12/72) 14.2% (31/219)
Diabetes mellitus 5.6% (4/71) 8.5%(8/94) 9.1% (14/154) 19.6% (9/46) 16.7% (12/72) 18.3% (40/219)
Tuberculosis 5.6% (4/71) 2.7% (6/219)
Immunosuppression 8.4% (13/154)
Chronic kidney disease 7.1% (11/154) 4.3% (2/46) 12.5% (9/72) 9.6% (21/219)
Splenectomy 1.3% (2/154)
Solid malignancy 5.6% (4/71) 6.4% (6/94) 0.7% (1/154) 10.9% (5/46) 11.1% (8/72) 14.2% (31/219)
Hematologic malignancy 11.7% (11/94) 0.7% (1/154) 5.9% (13/219)
Transplantation 6.4% (6/94) 0.7% (1/154) 2.8% (2/72) 1.8% (4/219)
Idiopathic CD4 lymphocytopenia 31.9% (30/94) 12.5% (9/72) 2.2% (1/46) 1.4% (3/219)
Without predisposing factors 60.6% (43/71) 55.3% (52/94) 66.9% (103/154) 43.5% (20/46) 25% (18/72) 10.5% (23/219)
a These studies displayed different format of age in the papers.
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study reported 61.9% of cryptococcosis cases were from immuno-
competent individuals in Taiwan (Chen and Lai, 2011). However,
a relatively small proportion (10.5%) of cryptococcosis in immono-
competent hosts has been reported in a study conducted in 20 hos-
pitals in Taiwan (Tseng et al., 2013), which was likely due to
distinct admission rates and preponderant department bias in dif-
ferent hospitals. Furthermore, studies from other Asian countries
where Chinese is the predominant ethnic group reported similar
results. For example, it has been shown that 96% of cryptococcosis
in Singapore were from immunocompetent individuals and only
6.7% of cryptococcosis were identiﬁed in immunocompromised
patients in Malaysia (Richardson et al., 1976; Tjia et al., 1985).
Similarly, in a study on HIV-uninfected patients with cryptococcal
meningitis in Vietnam, 81% of them (57 patients) had no clear pre-
disposing factor (Chau et al., 2010). Taken together, these reports
suggest that cryptococcosis predominantly occurs in immunocom-
petent hosts in the Chinese ethnic population that might be more
susceptible to cryptococcal infections than other ethnic groups.
Among patients with underlying conditions, HIV infection has
remained the most common risk factor for cryptococcosis in
China (Chen and Lai, 2011; Lui et al., 2006; Tseng et al., 2013;
Chen et al., 2012). Studies from mainland China, Taiwan, and
Hong Kong showed that the prevalence of cryptococcosis in
HIV/AIDS patients ranged from 12.9% to 24.7%, which is signiﬁ-
cantly lower than that in other regions of the world (Banerjee,
2005; Chen et al., 2000; Dromer et al., 1996, 2007; Friedman
et al., 2005; Jongwutiwes et al., 2008). The relatively low preva-
lence of cryptococcosis in HIV/AIDS patients in mainland China,
Taiwan, and Hong Kong may be attributed to several reasons.
Firstly, various AIDS control measures including national surveil-
lance and civil campaigns have signiﬁcantly slowed the spread of
HIV in China (Wang and Wang, 2010). At the end of 2009, only
740,000 HIV/AIDS cases were reported in China. Secondly, invasive
fungal infections were more common in patients with low CD4+ T
cells and the incidence of cryptococcosis among HIV-infected
patients declined rapidly due to the wide use of ﬂuconazole and
the introduction of HAART in the past decade (Friedman et al.,
2005; Kaplan et al., 2000; Shen et al., 2007). Thirdly, the majorityof HIV-infection cases in China were reported in less developed
areas such as Yunnan, Guangxi, and Henan (Wang and Wang,
2010). Poor hygiene and medical services limited the outpatient
rate, and delay the diagnosis and treatment of cryptococcal menin-
gitis in many patients. The relationship between HIV status and
cryptococcosis incidence remained to be further illuminated in
China. Other than HIV infections, several conditions such as
autoimmune diseases, immunosuppressant utilization, malig-
nancy, diabetes, and organ transplantation were also important
predisposing factors for cryptococcosis (See Table 2). It was note-
worthy that 14% and 12% of cryptococcosis patients in China had
tuberculosis and liver diseases, respectively, which is consistent
with the high prevalence of Mycobacterium and HBV infection in
China (Chen et al., 2012).
Overall, HIV-uninfected patients were the majority of the sus-
ceptible population to cryptococcosis in China, in contrast to most
other countries. In order to investigate the potential genetic predis-
position to cryptococcosis in the Chinese population, Ou et al. per-
formed a case-controlled study about the association between
mannose-binding lectin (MBL) polymorphisms and the develop-
ment of cryptococcal meningitis in non-HIV patients (Ou et al.,
2011). MBL, an important member of pathogen recognition recep-
tors (PRRs), is essential for activating host innate immunity. The
authors found that the genotypes underlying deﬁcient MBL pro-
duction was associated with cryptococcal meningitis (P = 0.039,
OR = 2.09), particularly, in immunocompetent patients (P = 0.028,
OR = 2.51), suggesting that MBL-deﬁciency is a genetic predisposi-
tion to cryptococcal meningitis in the Chinese Han ethnicity.
However, the study from Australia did not identify a statistically
signiﬁcant association between MBL deﬁciency and cryptococcosis
in immunocompetent hosts, which might be attributed to the
small sample size (36 patients), characteristics of pathogen consti-
tution, and ethnic factors (Eisen et al., 2008). In 2012, the associa-
tion between FCGR (Fc-gamma receptors FccRs coding genes)
polymorphisms and cryptococcal meningitis was analyzed in 117
patients and 190 healthy controls by multiplex SNaPshot genotyp-
ing (Hu et al., 2012). The investigation revealed that the FCGR2B
232I/T genotype was associated with cryptococcal meningitis in
HIV-uninfected individuals (P = 0.016, OR = 0.542), while no
Table 3
Clinical features of non-HIV-associated cryptococcosis in immunocompetent and immunocompromised hosts in three studies from China.
Parameter Zhu et al. (2010) Shih et al. (2000) Lui et al. (2006)
Mean/% (N/total or range) Mean/% (N/total or range) Mean ± SD/% (N/total)
Predisposed Normal hosts P Predisposed Normal hosts P Predisposed Normal hosts
Number of patients 51 103 30 64 8 16
Age (yr) 48 (14, 67) 35 (9, 75) 0.0001
Time to diagnosis (month) 30 (1, 124) 40 (6, 2890) 0.0062 14 (1900) 29 (1300) 0.015 15.3 ± 6.9 34.4 ± 7.7
Symptoms
Fever >39 C 41.2% (21/51) 16.5% (17/103) 0.001
Coma 7.8% (4/51) 11.7% (12/103) 0.466
Seizure 17.7% (9/51) 34.0% (35/103) 0.035
Cerebral herniation 7.8% (4/51) 25.2% (26/103) 0.01
Meningeal sign 46.7% (14/30) 79.7% (51/64) 0.002
Fungemia 23% (7/30) 9% (6/64) 0.07 25% (2/8) 0 (0/16)
Lymphocyte in blood 1000 (59, 10,423) 1500 (200, 9219) 0.02
CSF
WBC 63 (0, 756) 100 (0, 1030) 0.0611 20 (0, 306) 77 (0, 1098) 0.004 53.9 ± 36.8 108.4 ± 25.1
Cryptococcal antigen 1280 (10, >1280) 1280 (1, >1280) 0.7805 512 (8, 16,348) 192 (0, 16,348) NS 643.4 ± 576.3 810.0 ± 354.8
Cranial imaging
Parenchymal lesions (MRI) 88.9% (16/18) 61.7% (29/47) 0.034
Hydrocephalus (MRI/CT) 7.4% (2/27) 20.9% (14/67) 0.1 23% (4/17) 49% (23/47) 0.07 12.5% (1/8) 31.3% (5/16)
Meningeal enhancement (CT) 23.5% (4/17) 57.4% (27/47) 0.02
Hypodense lesion (CT) 0% (0/17) 23.7% (9/47) 0.05
Surgical procedure 5.9% (3/51) 23.3% (24/103) 0.007
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FCGR3B genotypes and cryptococcal meningitis. The results suggest
that FccRIIB polymorphisms are another important genetic factor
contributing to cryptococcal meningitis in HIV-uninfected
Chinese individuals. In addition to MBL and FCGR, genetic varia-
tions of other PRRs such as Toll-like receptors (TLRs) and
NOD-like receptors (NLRs) might also be associated with the devel-
opment of cryptococcal infections (unpublished data) (Zhu et al.,
2014). Identiﬁcation of other genes involved in cryptococcal infec-
tions may allow us to develop more effective therapy for the treat-
ment of cryptococcosis.
5. Clinical manifestations and management of cryptococcosis in
China
The central nervous system (CNS) and lungs are the most fre-
quently involved organs in cryptococcosis. According to the latest
literature review of cryptococcosis in mainland China (1985–
2010), CNS and pulmonary infections occurred in 83.4%
(7315/8769) and 13.0% (1142/8769) of cryptococcosis (Chen
et al., 2012). High prevalence of CNS involvement in cryptococcosis
patients has also been reported in Taiwan (58.9%) and Hong Kong
(CNS, 67.4%) (Lui et al., 2006; Tseng et al., 2013). In addition, a
study reported that C. gattii infections presented more often with
CNS involvement (100%, n = 9) than C. neoformans (57.1%,
n = 210) in China, which is different from the reports in other coun-
tries (Speed and Dunt, 1995; Tseng et al., 2013). However, this phe-
nomenon should be conﬁrmed by studies of larger sample size.
Clinical features of cryptococcosis vary in different susceptible
populations, presumably depending on initial pathogen load, host
immune status, and geographic or ethnic factors. As mentioned
above, cryptococcal infections in China mainly occurred in
non-HIV individuals, especially otherwise healthy hosts. Zhu
et al. analyzed the clinical features of cryptococcal meningitis in
immunocompetent hosts in a Chinese tertiary care hospital
(1997–2007, See Table 3) (Zhu et al., 2010). Compared to immuno-
compromised hosts, previously healthy patients were 10 years
younger and their time to diagnosis took longer. Additionally,
immunocompetent patients exhibited more severe neurologicalcomplications such as cerebral herniation, coma, seizure, and
hydrocephalus than immunocomprised patients, and thus experi-
enced more surgical shunt procedures. However, high fever and
parenchymal lesions in brains were more common in immuno-
compromised patients. Similar differences in clinical manifesta-
tions between these two groups of patients have also been
reported in Taiwan and Hong Kong (See Table 3) (Lui et al., 2006;
Shih et al., 2000). Immunocompetent patients often presented with
longer symptom durations and typical meningitis (meningeal signs
and CT scan ﬁndings), which is likely due to more robust host
immune responses (higher CSF cell counts and systemic lympho-
cyte counts). Conversely, immunocompromised patients tended
to have higher fungal burden and higher incidence of disseminated
infection (fungemia) (Shih et al., 2000). For example, HIV-infected
patients often had higher serum cryptococcal antigen titers
(P512), higher positive rate of fungal cultures from CSF and blood,
and more severe symptoms or even systemic dissemination of
infections than non-HIV hosts (Liao et al., 2012; Tseng et al.,
2013; Yu et al., 2012). Similarly, it has been reported that crypto-
coccal meningitis patients with HBV infection exhibited higher
positive CSF culture, more extraneural involvements, and lower
inﬂammatory responses than HBV-negative patients (Zhong
et al., 2014). Despite lack of serious underlying diseases, immuno-
competent individuals with cryptococcosis exhibited similar treat-
ment responses and prognosis as immunocompromised patients. It
has been reported that no statistical differences in the overall mor-
tality at one year were identiﬁed between these two groups of
cryptococcosis patients (P = 0.69) (Zhu et al., 2010). In this retro-
spective study, coma, cerebral herniation, non-amphotericin
B-based initial therapy, and delayed diagnosis (>120 days) were
identiﬁed as independent risk factors of mortality of cryptococcosis
patients. Other studies also reported that initial consciousness
level, hydrocephalus, high CSF antigen titers, and underlying dis-
eases such as malignancy, active HBV infection, and liver cirrhosis
were poor prognostic factors for non-HIV-infected cryptococcosis
patients (Liao et al., 2012; Lu et al., 1999; Lui et al., 2006; Shih
et al., 2000; Zhong et al., 2014).
The incidence of pulmonary cryptococcosis in China and other
countries have signiﬁcantly increased in the past decades
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nosis due to the wide use of serological testing and improved radi-
ological examination may lead to the increased incidence of
pulmonary cryptococcosis. Similar to CNS involvement, pulmonary
cryptococcosis mainly occurred in the HIV-uninfected population
in China, and the majority of patients were immunocompetent.
According to a review by Zhang, 69.7% (404/580) of pulmonary
cryptococcosis cases had no underlying conditions and only 3.6%
(21/580) pulmonary cryptococcosis patients had HIV infection
(Zhang, 2009), which is consistent with several other
single-center reports (Chang et al., 2006; Yu et al., 2012; Zhang
et al., 2012). The most common symptoms of pulmonary crypto-
coccosis are cough, expectoration, chest tightness, fever, and other
nonspeciﬁc manifestations. The severity depends mainly on host
immune status. For example, a large proportion of immunocompe-
tent patients (24–85.4%) were asymptomatic or had mild symp-
toms compared to immunocompromised patients (Ye et al.,
2012; Yu et al., 2012; Zhang et al., 2012). For these reasons, some
pulmonary cryptococcosis cases may be misdiagnosed as other
lung diseases such as cancer and pneumonia. In addition, diagnosis
of some cases of cryptococcal infection was only conﬁrmed
through incidental radiologic and/or histopathological examina-
tions. The most frequent radiological signs of pulmonary crypto-
coccosis were single or multiple nodular masses and patchy
consolidations mainly in subpleural areas and lower lung ﬁelds.
The lesion patterns were primarily associated with host immune
status. Generally, extensive pulmonary involvement and pneu-
monic inﬁltrates such as cavitation within nodules and parenchy-
mal consolidation were signiﬁcantly more common in
immunocomprised patients than immunocompetent patients
(Chang et al., 2006; Zhang et al., 2012). Histopathologically, initial
pulmonary lesions gradually developed into granulomas in
immunocompetent patients, but they frequently disseminate in
the lungs in immunocomprised patients. In general, pulmonary
cryptococcosis in HIV-uninfected patients has a good prognosis
due to early diagnosis and appropriate intervention. The majority
of asymptomatic cryptococcosis in immunocompetent undergo
spontaneous remission even without antifungal therapy.
In long-term research and practice, Chinese doctors gradually
developed their own experiences on the management of crypto-
coccal infections, especially in HIV-uninfected patients. In a study
by Zhu et al., non-amphotericin B (AmB)-based initial therapy
had been identiﬁed as the strongest independent factor associated
with poor prognosis of cryptococcosis (Zhu et al., 2010). Compared
to other antifungal drugs used in initial therapy, initial therapy
with AmB resulted in higher rates of overall responses at either
week 2 or 10, and signiﬁcantly lower overall mortality at one year.
In addition, it has been reported that intrathecal administration of
AmB, a special treatment for CNS cryptococcosis, was an effective
adjunctive treatment for many cryptococcosis patients in China,
although it is no longer used in most countries and not recom-
mended by the guidelines (Perfect et al., 2010). In the protocol of
intrathecal AmB administration, AmB was diluted in sterile water,
mixed with 4–5 ml auto-CSF and 1–2 mg dexamethasone, and
infused slowly via lumbar injection (increasing from 0.1 to 1 mg,
twice to three times per week). The regimen was continued for
about 8 weeks until CSF cultures were negative. Among the 40
CNS cryptococcosis patients who received a combination of
intrathecal and intravenous injection of AmB in Shanghai
Changzheng Hospital, 39 patients were cured without recurrence
(Yao et al., 2005). Chen et al. also reported that the combination
of intrathecal and intravenous injection of AmB cured 683 (33%)
of 1385 CNS cryptococcosis patients in China (Chen et al., 2012).
As an adjunctive therapy, intrathecal injection of AmB enhanced
the overall effectiveness from 72% to 74% (P < 0.05) and decreased
the mortality from 28% to 26% (P < 0.05), likely due to its role inelevating the concentration of AmB in CSF and reducing the
intracranial pressure. However, strict aseptic manipulation and
close observation of adverse drug reaction such as nosocomial
infection, retention of urine, and irritated cerebrospinal meningitis
were important for the success of this special treatment protocol.
An expert-guided protocol of two-phase therapy has been estab-
lished for the treatment of cryptococcal infections in
HIV-uninfected patients in China (Weng et al., 2010; Yao et al.,
2005). For CNS infections, patients receive AmB both intravenously
(0.5–1 mg/kg d) and intrathecally, and 5-Fluorocytosine for at least
8 weeks in the induction stage, followed by ﬂuconazole or itra-
conazole therapy for at least 12 weeks in the maintenance stage.
In this protocol, AmB administration in the induction stage was
much longer than the 2 weeks recommended in the guidelines
by the Infectious Diseases Society of America (Perfect et al.,
2010). Based on Chinese physicians’ experience, patients with
cryptococcal meningoencephalitis usually need an average of
8 weeks of initial AmB therapy to obtain negative results of CSF
culture (Yao et al., 2005). However, the efﬁcacy of these two regi-
ments should be evaluated and compared to further improve the
treatment of cryptococcosis based on large-scale clinical trials.
6. Conclusion
Over the past decades, signiﬁcant progress has been made in the
ecological distribution, population genetics, molecular epidemiol-
ogy, and clinical features of Cryptococcus and cryptococcosis in
China. However, there are still many unanswered questions. First,
the ecological characteristics of C. neoformans inwestern and north-
ern regions, and the environmental niche of C. gattii in China remain
unclear. In addition, the signiﬁcance of environmental strains of
Cryptococcus spp. in human infections needs to be addressed.
Second, most of the molecular and epidemiological data originated
from single-center retrospective studies, which cannot reﬂect the
comprehensive prevalence and fungal burden of cryptococcosis in
China. Therefore, effective nationwide surveillance of invasive fun-
gal infections is important for this purpose. Questions such as the
relationship between speciﬁc genotypes and phenotypes, the
genetic diversity of Chinese clinical isolates and their association
with global strains, and why immunocompetent individuals are
more susceptible to cryptococcal infections than immunocom-
prised individuals in China, remain to be further elucidated.
Finally, diagnosis and treatment of cryptococcal infections are still
a big challenge in many regions (especially the undeveloped west-
ern provinces) in China due to limited experience and molecular
tools.
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